Description: Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.
Home Page: www.orchard-tx.com
ORTX Technical Analysis
108 Cannon Street
London,
EC4N 6EU
United Kingdom
Phone:
44 20 3 808 8286
Officers
| Name | Title |
|---|---|
| Dr. Bobby Gaspar M.D., Ph.D. | CEO, Member of Scientific Advisory Board & Exec. Director |
| Mr. Frank E. Thomas | Pres & COO |
| Dr. Nicoletta Loggia Ph.D. | Chief Technical Officer |
| Dr. Fulvio Mavilio Ph.D. | Chief Scientific Officer |
| Ms. Renee T. Leck | Director of Investor Relations |
| Benjamin Navon | Director of Corp. Communications |
| Mr. John Cerio | Chief Human Resource Officer |
| Mr. Robin Kenselaar | Sr. VP & GM of EMEA Commercial Operations |
| Mr. Braden Parker | Chief Commercial Officer |
| Dr. Leslie Meltzer Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4506 |
| Price-to-Sales TTM: | 3.4512 |
| IPO Date: | 2018-10-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 259 |